<DOC>
	<DOCNO>NCT00485004</DOCNO>
	<brief_summary>To evaluate optimal management focal in-stent restenosis drug-eluting stent implantation sirolimus-eluting implantation versus cut balloon angioplasty</brief_summary>
	<brief_title>Focal In-stent Restenosis After Drug-Eluting Stent</brief_title>
	<detailed_description>Following angiography , patient focal DES restenosis ( lesion length â‰¤ 10mm ) diameter stenosis &gt; 50 % visual estimation document myocardial ischemia symptom angina , eligible PCI without exclusion criterion randomize 1:1 : ) Cypher stent vs. b ) Cutting balloon angioplasty . All patient follow 1 year . Angiographic follow-up 9-months mandatory .</detailed_description>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . The patient must least 18 year age . 2 . Restenosis drugeluting stent ( &gt; 50 % visual estimate ) 3 . Lesion length &lt; 10 mm ( focal ISR ) 4 . Patients stable ( CCS class 1 4 ) acute coronary syndrome ( unstable angina pectoris Braunwald class IB , IC , IIB , IIC , IIIB , IIIC NSTEMI ) patient atypical chest pain without symptom document myocardial ischemia , amenable stentassisted percutaneous coronary intervention 5 . The patient guardian agrees study protocol schedule clinical angiographic followup , provide informed , write consent , approve appropriate Institutional Review Board/Ethical Committee respective clinical site . 1 . The patient know hypersensitivity contraindication follow medication : Heparin Aspirin Both Clopidogrel TIclopidine Sirolimus elute stent Stainless steel and/or Contrast medium ( patient document sensitivity contrast effectively premedicated steroid diphenhydramine [ e.g . rash ] may enrol . Patients true anaphylaxis prior contrast medium , however , enrol ) . 2 . Systemic ( intravenous ) Sirolimus use within 12 month . 3 . Female childbearing potential , unless recent pregnancy test negative , possibly plan become pregnant time enrollment study . 4 . History bleed diathesis know coagulopathy ( include heparininduced thrombocytopenia ) , refuse blood transfusion . 5 . Gastrointestinal genitourinary bleeding within prior 3 month , major surgery within 2 month . 6 . Current know current platelet count &lt; 100,000 cells/mm3 Hgb &lt; 10 g/dL . 7 . Noncardiac comorbid condition present life expectancy &lt; 1 year may result protocol noncompliance ( per site investigator 's medical judgment ) . 8 . Patients actively participate another drug device investigational study , complete primary endpoint followup period . 9 . Patients EF &lt; 30 % . 10 . Acute MI patient within symptom onset &lt; 12 hour need primary angioplasty 11 . Creatinine level 3.0mg/dL dependence dialysis . 12 . Severe hepatic dysfunction ( AST ALT 3 time upper normal reference value ) . 13 . Patients leave main stem stenosis leave main instent restenosis create DES ( &gt; 50 % visual estimate )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Coronary artery disease</keyword>
	<keyword>Stent</keyword>
	<keyword>Angioplasty</keyword>
</DOC>